New Peer-Reviewed Paper in Antibodies Highlights Pfizer’s Outstanding Results with CHO 4Tx®
At the heart of this publication, entitled “A Robust, High-Titer, Semi-Automated, and In-Culture Antibody-Capturing Transient CHO Platform Technology” and co-authored by Pfizer, Magellan Biologics, and ExcellGene, is our CHO 4Tx® system – a high-yield, seamless transient CHO platform developed by Magellan Biologics and ExcellGene. The study demonstrates how CHO 4Tx® delivered exceptional performance as the […]